TY  - JOUR
A1  - Pettengell, Ruth
A1  - Sebban, Catherine
A1  - Zinzani, Pier Luigi
A1  - Derigs, Hans-Günter
A1  - Kravchenko, Sergey
A1  - Singer, Jack W.
A1  - Theocharous, Panteli
A1  - Wang, Lixia
A1  - Pavlyuk, Mariya
A1  - Makhlouf, Kahina M.
A1  - Coiffier, Bertrand
T1  - Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B‐cell non‐Hodgkin lymphoma : post‐hoc analyses from a phase III trial
T2  - British journal of haematology
N2  - This post hoc analysis of a phase 3 trial explored the effect of pixantrone in patients (50 pixantrone, 47 comparator) with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL) confirmed by centralized histological review. Patients received 28-d cycles of 85 mg/m2 pixantrone dimaleate (equivalent to 50 mg/m2 in the approved formulation) on days 1, 8 and 15, or comparator. The population was subdivided according to previous rituximab use and whether they received the study treatment as 3rd or 4th line. Median number of cycles was 4 (range, 2–6) with pixantrone and 3 (2–6) with comparator. In 3rd or 4th line, pixantrone was associated with higher complete response (CR) (23·1% vs. 5·1% comparator, P = 0·047) and overall response rate (ORR, 43·6% vs. 12·8%, P = 0·005). In 3rd or 4th line with previous rituximab (20 pixantrone, 18 comparator), pixantrone produced better ORR (45·0% vs. 11·1%, P = 0·033), CR (30·0% vs. 5·6%, P = 0·093) and progression-free survival (median 5·4 vs. 2·8 months, hazard ratio 0·52, 95% confidence interval 0·26–1·04) than the comparator. Similar results were found in patients without previous rituximab. There were no unexpected safety issues. Pixantrone monotherapy is more effective than comparator in relapsed or refractory aggressive B-cell NHL in the 3rd or 4th line setting, independently of previous rituximab.
KW  - pixantrone
KW  - salvage therapy
KW  - B-cell non-Hodgkin lymphoma
KW  - rituximab
KW  - post hoc study
Y1  - 2017
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/43685
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-436853
SN  - 1365-2141
SN  - 0007-1048
N1  - This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes
VL  - 174
IS  - 5
SP  - 692
EP  - 699
PB  - Wiley-Blackwell
CY  - Oxford [u. a.]
ER  -